South Asian Cardiovascular Risk Authors: Dinesh K Kalra, Deepak Vedamurthy, Nisha Hosadurg, Abhinav Goyal, Milan Gupta, Neha Pagidipati, Leandro Slipczuk, Damini Dey, Anurag Mehta, Parag Joshi, Lohendran Baskaran, Nathan Wong, Salim S Virani Published: 2026 ABSTRACT AbstractSouth Asians (SAs) experience a disproportionately high burden of premature atherosclerotic cardiovascular disease, yet conventional risk assessment algorithms often underestimate their cardiovascular risk. This review highlights the evolving role of atherosclerosis imaging, namely, coronary artery calcium scoring and coronary computed tomographic angiography (CTA), as complementary tools for earlier detection and refined risk stratification in SAs. The authors review evidence demonstrating earlier appearance and greater coronary plaque burden in SAs, often accompanied by higher risk plaque features and inflammation, even in the setting of a zero or low coronary artery calcium score. Advances in coronary CTA, including artificial intelligence–enabled plaque quantification, perivascular fat attenuation index, and computed tomography–derived fractional flow reserve, enable the characterization of high-risk vascular biology and may guide targeted preventive therapies. Coronary artery calcium scoring can refine risk in SAs as broadly as in other ethnic groups. However, in younger SAs who may not yet have developed calcified plaque, the selective and judicious application of coronary CTA to visualize noncalcified plaque in targeted high-risk individuals offers an evolving strategy for earlier and personalized initiation of aggressive preventive therapies.Key words: atherosclerosis, prevention, risk assessment South Asians (SAs)—individuals from India, Pakistan, Bangladesh, Sri Lanka, Nepal, Bhutan, and the Maldives—represent one of the fastest growing ethnic groups worldwide, accounting for 25% of the world’s population currently. Nevertheless, they bear a disproportionate burden (∼50%) of the global burden of atherosclerotic cardiovascular disease (ASCVD) and cardiovascular (CV) mortality.1,2 SAs (both natives and the diaspora) experience an earlier onset of coronary artery disease (CAD), higher cardiometabolic risk, and greater case fatality from CAD than other racial and ethnic groups, even after adjusting for traditional risk factors.3,4 SA communities that have settled in Western countries demonstrate a higher prevalence of diabetes, adverse lipid profiles, hypertension, and obesity compared with native populations, reflecting the combined effects of genetic susceptibility, urbanization, and lifestyle transitions.3,5,6 In a comparative analysis of major Asian American subgroups in the United States, Asian Indians exhibited the highest heart disease mortality: 111.8 per 100,000 among women and 152.8 per 100,000 in men.7 Metabolic risk is similarly amplified: in a U.S. cohort of more than 2 million adults, SAs had one of the highest incidences of diabetes (17.2 per 1,000 person-years), more than double the incidence observed in White individuals.8 Asian Indians have also been shown to have a higher prevalence of premature hypertension and visceral obesity, which increases ASCVD risk.9, 10, 11 A distinct cardiometabolic phenotype underlies this excess risk, characterized by insulin resistance at lower body mass index (BMI), visceral adiposity, atherogenic dyslipidemia, elevated lipoprotein(a) (Lp[a]), and proinflammatory adipokine patterns.12 These abnormalities contribute to the accelerated development of subclinical atherosclerosis, often in the form of noncalcified, rupture-prone “vulnerable” plaque, and this enhanced risk is not fully captured by traditional risk calculators such as the pooled cohort equations or QRISK3.13 As a result, ASCVD risk is frequently underestimated in SAs, leading to delayed initiation of preventive therapies.14,15 Because of this concern, SA ethnicity is now designated as a risk-enhancing factor in current U.S. and European preventive guidelines.16,17 Furthermore, given these limitations and the higher prevalence of coronary atherosclerosis at a younger age, advanced imaging tools such as coronary artery calcium scoring (CACS) and coronary computed tomography angiography (CTA) have emerged as important adjuncts for SA risk assessment. Although CACS is recommended in several guidelines worldwide to refine risk in intermediate-risk individuals and guide preventive therapy, it often misses atherosclerosis in younger individuals, as plaque calcification typically takes several years to manifest after its initiation. Coronary CTA provides direct visualization of plaque volume, composition, and high-risk features, enabling the earlier identification of vulnerable disease that traditional markers and CACS may miss in this population. Integrating coronary CTA–derived metrics into clinical practice offers a pathway toward more accurate stratification and earlier intervention for this uniquely high-risk group.18 In this review we highlight how CACS and coronary CTA offer a more accurate and actionable framework for early detection, individualized risk stratification, and targeted prevention in this high-risk population. A comprehensive literature search was conducted across PubMed/MEDLINE, Embase, the Cochrane Library, and Google Scholar from 1990 through 2025, using a combination of Medical Subject Headings and Emtree terms and keywords related to SA ethnicity, ASCVD, coronary artery calcium (CAC), coronary CTA, plaque composition, artificial intelligence (AI)–enabled plaque quantification, and inflammatory or metabolic risk markers. Search terms included “South Asian,” “Asian Indian,” “coronary artery disease,” “coronary artery calcium,” “coronary CT angiography,” “high-risk plaque,” “low-attenuation plaque,” “lipoprotein(a),” “visceral adiposity,” “perivascular fat attenuation index,” and “FFR-CT.” Searches were limited to human studies published in English, and reference lists of key cohort studies (MASALA [Mediators of Atherosclerosis in South Asians Living in America], MESA [Multi-Ethnic Study of Atherosclerosis], SABRE [Southall and Brent Revisited], and the UK Biobank) and major clinical trials were manually reviewed to identify additional eligible studies. Limitations of Traditional ASCVD Risk Assessment Tools in SAs Although several population-specific risk assessment tools exist to calculate the risk for major adverse CV events (MACE) on the basis of risk factor profiles, none of the currently available models has been well studied in the SA population. The widely used CV risk assessment algorithms—including the pooled cohort equations, SCORE2, and QRISK3—underestimate risk in SAs.19, 20, 21, 22 In a prospective UK Biobank cohort, SAs exhibited nearly twice the risk for ASCVD compared with European participants; however, this elevated risk was not adequately captured by either the pooled cohort equations or QRISK3.3 A few risk models incorporate SA ethnicity as a risk modifier, including JBS3 and QRISK3 (the UKPDS [UK Prospective Diabetes Study] Risk Engine contains an ethnicity field but does not treat SA ancestry as an independent predictor).19,23 In a coronary computed tomographic angiographic study of SA and White patients with type 2 diabetes, JBS3 correlated best with CAC and obstructive CAD among 4 scores compared (UKPDS, Framingham risk score, ASCVD, and JBS3).24 In general, the limited performance of conventional risk prediction models among SAs reflects their underrepresentation in derivation cohorts and an overreliance on traditional risk factors, which do not adequately capture the population’s distinct pathophysiological heterogeneity or incorporate important contributors such as family history, Lp(a), environmental exposures, genetic predisposition, adiposity, and metabolic dysfunction–associated steatotic liver disease. For comparable levels of traditional CV risk factors—including age, blood pressure, lipid levels, and smoking—SAs exhibit a greater burden of subclinical coronary atherosclerosis on imaging. This discordance between conventional risk profiles and underlying plaque burden reflects earlier and more aggressive atherosclerotic remodeling, underscoring the limitations of risk factor–based assessment and the need for imaging-based and other strategies (such as machine learning, wearables, tracking environmental pollutant exposures, etc) to more accurately identify latent disease in this population.25, 26, 27 Beyond the underperformance of conventional risk factors, distinct anthropometric and metabolic characteristics further contribute to risk misclassification in SAs. Traditional BMI thresholds for overweight (≥25 kg/m2) and obesity (≥30 kg/m2), which were derived from White populations, underestimate the definition of obesity in SAs. For this reason, the Lipid Association of India and the National Lipid Association both recommend lower BMI cutpoints for SAs: ≥23 kg/m2 for overweight and ≥25 kg/m2 for obesity.2,11 To better capture visceral adiposity, the International Diabetes Federation and the World Heart Federation propose waist circumference thresholds for abdominal obesity: ≥94 cm in European men, ≥90 cm in Asian men (including SA men), and ≥80 cm in women across both groups.28 In addition to visceral adiposity, SAs exhibit a higher prevalence of nontraditional factors, including chronic inflammation, endothelial dysfunction, and dysfunctional high-density lipoprotein (HDL), a family history of premature CAD, higher levels of Lp(a), environmental pollution, genetic predisposition, adiposity, and metabolic dysfunction–associated steatotic liver disease, which further amplify vascular risk.29,30 Together, these limitations highlight the urgent need for SA-specific risk assessment frameworks that better reflect the unique metabolic and atherosclerotic profiles of this high-risk population. The limitations of traditional risk calculators and unique aspects of SA CV risk are highlighted in Table 1. Table 1Advantages of Cardiac Computed Tomographic Imaging (CACS and Coronary CTA) Over Traditional Risk Assessment Tools in South AsiansFeatureTraditional Risk Scoring ToolsCACSCoronary CTA (With Respect to SAs)Noncalcified plaque detectionNoNoYesDetects NCP at an earlier stage, which is more prevalent in SAsPlaque composition characterizationNoNoYesIdentifies HRP: LAP, PR, NRS, which are common in SAsTotal plaque burden measurementNoPartial (calcified only)YesComprehensive plaque quantificationAssessment of biologic activityNoNoYesEvaluates vascular inflammation (PVAT FAI)Risk reclassification accuracyLimitedModerateHighCorrects systematic risk underestimationUtility in younger individualsPoorLimitedHighIdentifies early/preclinical ASCVDGuidance of preventive therapyIndirectLimitedStrongInforms earlier statins and therapy intensificationOutcome benefitIndirectSurrogatePotential for improved outcomes via earlier detection and preventionCost$$$$$$$Availability+++++++++Coronary CTA improves risk stratification by directly visualizing plaque composition, quantifying total plaque burden, and assessing vascular inflammation, providing a markedly more accurate assessment of ASCVD risk in this population.ASCVD = atherosclerotic cardiovascular disease; CACS = coronary artery calcium scoring; CTA = computed tomographic angiography; FAI = fat attenuation index; HRP = high-risk plaque; LAP = low-attenuation plaque; NCP = noncalcified plaque; NRS = napkin-ring sign; PR = positive remodeling; PVAT = perivascular adipose tissue; SA = South Asian. Advantages of Cardiac Computed Tomographic Imaging (CACS and Coronary CTA) Over Traditional Risk Assessment Tools in South Asians Coronary CTA improves risk stratification by directly visualizing plaque composition, quantifying total plaque burden, and assessing vascular inflammation, providing a markedly more accurate assessment of ASCVD risk in this population. ASCVD = atherosclerotic cardiovascular disease; CACS = coronary artery calcium scoring; CTA = computed tomographic angiography; FAI = fat attenuation index; HRP = high-risk plaque; LAP = low-attenuation plaque; NCP = noncalcified plaque; NRS = napkin-ring sign; PR = positive remodeling; PVAT = perivascular adipose tissue; SA = South Asian. Pathophysiology Underlying the Increased ASCVD Risk in SAs Metabolic and environmental influences Although conventional risk factors—such as smoking, hypertension, diabetes, obesity, physical inactivity, and adverse dietary patterns—remain important drivers of ASCVD in SAs, they do not fully account for this population’s disproportionately high CV prevalence and mortality. SAs exhibit an amplified burden of additional, population-specific risk enhancers, including atherogenic dyslipidemia, visceral adiposity with marked insulin resistance, an unfavorable adipokine and inflammatory profile, elevated Lp(a), and distinct dietary and psychosocial influences (Figure 1). These factors collectively create a cardiometabolic environment that accelerates atherosclerosis beyond what traditional risk factors alone would predict. In the PURE (Prospective Urban Rural Epidemiology) study, CV disease (CVD) emerged as the leading cause of death in the SA cohort (33,583 adults from India, Bangladesh, and Pakistan), accounting for 35.5% of all deaths over 11 years of follow-up.31 A striking rural-urban divide was evident: rural communities experienced substantially higher age- and sex-adjusted CVD incidence (5.41 vs 4.73 per 1,000 person-years) and mortality (10.27 vs 6.56 per 1,000 person-years) compared with urban counterparts.31 The major mutually adjusted population-attributable fractions for CVD included hypertension (13.1%), high non-HDL cholesterol (11.1%), diabetes (8.9%), low education (7.7%), abdominal obesity (6.9%), and household air pollution (6.1%). For all-cause mortality, low education (18.9%), low physical strength (14.6%), poor diet (6.4%), diabetes (5.8%), tobacco use (5.8%), and hypertension (5.5%) were the dominant contributors.31 Pathophysiological Factors Accounting for the Higher ASCVD Risk in SAs Multiple genetic, metabolic, and environmental factors contribute to early atherosclerotic cardiovascular disease (ASCVD) in South Asians (SAs). Genetic variants, elevated lipoprotein (a) (Lp[a]), fetal undernutrition, and the SA newborn phenotype create early vulnerability. An atherogenic diet, visceral adiposity at normal body mass index (BMI), insulin resistance, atherogenic dyslipidemia, and inflammation accelerate endothelial dysfunction and noncalcified plaque formation, leading to early-onset ASCVD. APOB = apolipoprotein B; APOA5 = apolipoprotein A5; APOE = apolipoprotein E; CACS = coronary artery calcium score; HDL = high-density lipoprotein; hsCRP = high-sensitivity C-reactive protein; IL-6 = interleukin-6; LDL = low-density lipoprotein; miR = microRNA; PHACTR1 = phosphatase and actin regulator 1; PVAT = perivascular adipose tissue; SORT1 = sortilin 1. SAs exhibit a distinctive pattern of atherogenic dyslipidemia that substantially contributes to their heightened burden of premature ASCVD. Multiple studies consistently confirm a characteristic triad of elevated triglycerides, low HDL cholesterol, and disproportionately high apolipoprotein B, despite low-density lipoprotein (LDL) cholesterol levels often falling within “normal ranges.”18 This discordance reflects a predominance of small, dense LDL particles, which are strongly associated with insulin resistance and are more than twice as prevalent in SAs compared with Europeans.32 These qualitative lipid abnormalities—smaller and denser LDL, along with a tendency for higher oxidation and aggregation, and reduced HDL functionality—create a proinflammatory and proatherogenic milieu that accelerates plaque formation.32, 33, 34 Elevated cholesteryl ester transfer protein activity, approximately 30% higher in SAs, further contributes to low HDL cholesterol and increased LDL particle number, compounding the cardiometabolic burden.35 SAs have high rates of insulin resistance and diabetes. Early pancreatic beta-cell dysfunction, in addition to insulin resistance, contributes to the increased risk for diabetes.36 SAs have a high rate of visceral adiposity characterized by a high waist-to-BMI ratio, often referred to as the “hypertriglyceridemic waist.”37 SAs also develop metabolic dysfunction–associated steatotic liver disease at “lean BMI.”38 Dietary factors play an important role in increasing the risk for diabetes. SA dietary patterns increasingly feature refined carbohydrates and processed foods, with white rice, white flour, and added sugars accounting for more than 70% of daily caloric intake, often exceeding 330 g/day of carbohydrates, a threshold associated with increased diabetes risk.39 Environmental pollution plays a vital role in driving CV risk. In a large systematic review and meta-analysis of 18 prospective cohort studies involving more than 7.3 million individuals, long-term exposure to higher levels of fine particulate matter <2.5 μm was consistently associated with increased all-cause mortality (HR: 1.08), incident CVD (HR: 1.09), and CV mortality (HR: 1.12). Higher levels of fine particulate matter and other environmental pollutants (including air, soil, and noise) and high-temperature extremes are encountered in many urban areas in South Asia, often among the highest in the world.40,41 These findings highlight fine particulate matter as a potent, modifiable CV risk factor that contributes to atherosclerotic progression through oxidative stress, inflammation, and endothelial dysfunction.42 Lp(a) and genetic predisposition Lp(a) is an LDL-like particle with a cholesterol ester–rich core bound to apolipoprotein(a), a highly polymorphic protein composed of multiple Kringle IV repeats, and it is structurally analogous to plasminogen.43,44 Lp(a) is a genetically determined, causal risk factor for ASCVD, with circulating concentrations largely inherited, and the serum levels are not significantly influenced by lifestyle, diet, or exercise.45 SAs have the highest worldwide burden (about 469 million adults) of elevated Lp(a) levels, with about 25% of the population having levels above the “normal” range.22,44 However, elevated Lp(a) appears to potentiate the CV risk associated with metabolic dysfunction, particularly central adiposity as reflected by an increased waist-to-hip ratio.46 In the MASALA cohort, SAs demonstrated significantly higher median Lp(a) levels than Whites, Hispanics, and Chinese Americans, highlighting a population-wide predisposition that contributes to their elevated burden of premature CAD.47 In the INTERHEART case-control study, elevated Lp(a) (>50 mg/dL) was associated with an age- and sex-adjusted OR for myocardial infarction of 1.48 (95% CI: 1.32-1.67) in the pooled multiethnic population studied. The association was strongest among SAs (OR: 2.14), who also had the highest population-attributable risk (∼9.5%) among the 7 ethnic groups studied.48 In contrast, in the prospective UK Biobank cohort, the relative risk for incident ASCVD per 50 nmol/L increment in Lp(a) was similar across ethnic groups (adjusted HR: ∼1.10 in SAs vs ∼1.11 in European-ancestry participants), despite SAs’ having higher median Lp(a) concentrations. This apparent contrast with INTERHEART largely reflects methodological differences, that is, a case-control OR for Lp(a) > 50 mg/dL vs a prospective per-increment HR, and a myocardial infarction vs composite ASCVD endpoint rather than a true discrepancy in the strength of the Lp(a)-risk relationship.3 Additional genetic factors likely contribute to the enhanced ASCVD risk in SAs.49 A family history of CAD in a first-degree relative at any age was associated with a high CAC score (>300 Agatston units) in SAs living in the United States.50 This observation aligns with emerging genomic data revealing that several lipid genetic variants are disproportionately enriched in SAs. For instance, polymorphisms in APOA5, a key regulator of triglyceride hydrolysis, are more prevalent in SAs (rs662799 C-allele ∼20% vs ∼4% in Europeans) and contribute to the characteristic hypertriglyceridemia and excess of triglyceride-rich, apolipoprotein B–containing lipoproteins seen in this cohort.51 These lipid perturbations shape a metabolic milieu favoring small, dense LDL and triglyceride-rich lipoprotein particles, impaired HDL function, and increased oxidative modification of lipoproteins.32,52 Beyond traditional risk factors, several susceptibility loci identified through genome-wide association studies contribute to ASCVD risk in SAs. The most replicated is the chromosome 9p21 locus principally through effects on vascular smooth-muscle proliferation and senescence; this effect is directionally consistent in SAs with that in Europeans.53 This region modulates expression of cyclin-dependent kinase inhibitors (CDKN2A/2B) and the long noncoding RNA ANRIL (antisense noncoding RNA in the INK4 locus) influencing vascular smooth muscle cell proliferation, plaque remodeling, and plaque progression (Figure 1).54,55 A missense variant in APOA5 (rs2075291) also reached genome-wide significance for CAD in Asian Indian–inclusive cohorts, consistent with the gene’s role in triglyceride metabolism and this population’s characteristic hypertriglyceridemia and low HDL cholesterol.56 Additional loci include 6p24, where the PHACTR1 (phosphatase and actin regulator 1) variant rs9349379 influences endothelin-1 expression, and 1p13, where noncoding variation near SORT1 alters hepatic sortilin expression and very low density lipoprotein and apolipoprotein B secretion and LDL clearance, making it an important determinant of circulating LDL cholesterol.57,58 Together, these signals converge on pathways governing lipid handling, vascular remodeling, and plaque biology, amplifying ASCVD risk beyond what traditional risk factors alone can explain. Emerging work has also identified differentially expressed circulating microRNAs in SAs, such as miR-21 in atherogenic dyslipidemia and miR-128 in dysglycemia; however, these have not yet been validated against clinical CV outcomes.59,60 In addition, gene-environment interactions, such as fetal undernutrition followed by excessive caloric intake, have been hypothesized to contribute to changes that affect the development of chronic diseases, hypertension, and inflammatory processes, heightening the risk for atherosclerosis.61, 62, 63, 64, 65 Genetic adaptations that favor efficient energy storage predispose to metabolic dysregulation in modern conditions of caloric abundance and sedentary lifestyles.66 Multiple novel loci have been identified in SAs, which increase their predisposition for type 2 diabetes.67 Together, these genetic, metabolic, and environmental factors create a uniquely high-risk biological framework that markedly increases ASCVD susceptibility in SAs. Inflammation and adipokine dysregulation Elevated plasma high-sensitivity C-reactive protein (hsCRP), a systemic marker of inflammation, has been consistently associated with ASCVD events across multiple studies.68 In a prospective UK cohort of healthy men, Indian Asians exhibited significantly higher hsCRP concentrations than European Whites, corresponding to an estimated 14% increase in CAD risk.22,68 SAs tend to have elevated baseline hsCRP levels (∼ 1.9 mg/L), almost double the level considered low-risk in Western populations (<1 mg/L) considered low risk in Western populations.69 Adipocyte-derived adipokines further shape this inflammatory milieu. Adiponectin enhances fatty acid oxidation and insulin sensitivity, whereas leptin reflects overall adiposity and energy balance.70 Despite similar BMI, SAs demonstrate disproportionately low adiponectin and high leptin levels, a pattern consistent with dysfunctional adipose tissue and impaired leptin signaling.71,72 Chronic low-grade inflammation in SAs is likely driven by visceral adiposity and ectopic fat deposition.73 Even normal-weight SAs’ immune-cell inflammatory activity equaled that of centrally obese Europeans, highlighting that SAs have “dysfunctional” fat that generates inflammatory signals even at lower fat mass.73 This inflammation contributes to the early development of endothelial dysfunction and atherosclerosis.74 Interleukin-6 (IL-6) and tumor necrosis factor-α levels are proinflammatory cytokines secreted by adipose tissue and immune cells and correlate with insulin resistance, directly contributing to endothelial activation and plaque formation.69 Genetic variants influencing cytokine expression, such as IL-6 and tumor necrosis factor-α polymorphisms, are disproportionately represented in SAs and contribute to heightened innate immune activation.75 These inflammatory mediators disrupt endothelial homeostasis, reduce nitric oxide bioavailability, and promote leukocyte adhesion and plaque instability.76,77 Furthermore, endothelial dysfunction has been observed in young, ostensibly healthy SAs, suggesting a vasculature primed for atherogenesis via amplified oxidative stress and gene-environment interactions.78,79 An optical coherence tomography study of patients presenting with acute coronary syndromes (including 100 SAs) in which plaque erosion caused acute coronary syndromes more often than plaque rupture (57% vs 37%) supports this hypothesis. In that study, SAs had more prevalent high-risk or vulnerable plaque features, including high lipid index, thin-cap fibroatheroma, and layered plaque, consistent with the chronic inflammatory and prothrombogenic phenotype seen in SAs.30,80 Smaller coronary artery lumen size In the 1990s and early 2000s, a hypothesis emerged suggesting that SAs possess intrinsically smaller coronary arteries, potentially contributing to their elevated risk for CAD. This concept was reinforced by a 2001 UK study of patients undergoing coronary artery bypass grafting, which observed higher postoperative mortality among SAs despite no differences in traditional CV risk factors, raising the possibility that smaller coronary caliber may play a contributory role.81 Subsequently, several studies, primarily from the United Kingdom and the United States, examined coronary artery size as a potential risk modifier in SAs. However, results were inconsistent and frequently limited by methodological constraints. For example, Lip et al82 reported no significant differences in indexed mean coronary diameters between asymptomatic SA men (n = 39) and Caucasian men (n = 77) with angiographically normal coronary arteries. In contrast, Makaryus et al,83 studying symptomatic patients in the United States with angiographically normal coronary arteries, found significantly smaller indexed coronary diameters in SAs compared with Caucasians, particularly among men. However, these analyses did not adjust for key confounders—most notably diabetes, which was more prevalent among SAs and may have influenced coronary dimensions—limiting causal inference. More recently, a single-center Australian coronary computed tomographic angiographic study provided a more comprehensive assessment by evaluating coronary anatomy, luminal volume, left ventricular mass, and computed tomography–derived fractional flow reserve (FFR-CT) across SA, Caucasian, and East Asian patients undergoing clinically indicated imaging. Among individuals with no or minimal CAD, SAs had significantly smaller absolute minimal luminal diameters in the proximal left anterior descending and right coronary arteries than both comparator groups. In parallel, SAs exhibited the lowest left ventricular myocardial mass indexed to body surface area and the lowest FFR-CT values in the left anterior descending coronary artery territory, suggesting a potential functional consequence of reduced coronary caliber even in the absence of obstructive disease.84 Overall, studies evaluating coronary size in SAs have been limited by clinically heterogeneous populations, small sample sizes, incomplete adjustment for cardiometabolic confounders, and reliance on segment-level diameter measurements rather than volumetric or physiological metrics. Collectively, these investigations have not consistently demonstrated that indexed coronary volume is meaningfully reduced in SAs. Consequently, whether normalized coronary size is truly smaller in this population remains uncertain, and importantly, there is currently no compelling evidence that smaller coronary dimensions independently drive MACE in SAs. Coronary Computed Tomography for ASCVD Risk Assessment CACS The Lipid Association of India strongly emphasizes the early detection of subclinical atherosclerosis because conventional risk assessment substantially underestimates CV risk among Indians, who develop ASCVD at a younger age, with greater severity, and often at lower LDL cholesterol levels than Western populations. The Lipid Association of India recommends the early identification of subclinical atherosclerosis to enable the timely initiation of intensive lipid-lowering therapy, aiming to halt or reverse disease progression and reduce the burden of premature ASCVD in this high-risk population.85 CACS is a widely performed screening test, and CAC score has been demonstrated to be an independent predictor of MACE, even in multiethnic cohorts.86 Because of its low radiation exposure, noninvasiveness, and predictive capabilities, CACS should be prioritized as the method of choice when additional CV risk stratification is warranted.2 SA men exhibit higher, denser CAC levels with greater vessel involvement compared with other ethnic groups and women, particularly after 70 years of age.22,87,88 In SAs, both CAC density and CAC volume have been shown to be good predictors of ASCVD risk.89 Large population-based cohorts—including MASALA, DILWALE (DIL Wellness and Arterial Health Longitudinal Evaluation), MESA, and SABRE—have consistently shown that SAs have higher CAC burden and distribution patterns than most other ethnicities.90, 91, 92, 93, 94, 95 Among asymptomatic individuals with type 2 diabetes, SAs exhibit higher CAC scores and a significantly greater prevalence of obstructive CAD, particularly within the left anterior descending coronary artery, which also demonstrates the fastest progression of incident CAC.96 Modifiers of higher CAC volume and density trajectories in SAs include smoking, elevated Lp(a), and physical activity, with family history of premature CAD exerting an additional and substantial influence.97 However, significant limitations should be recognized, such as the potential for false reassurance in SAs with CAC = 0, as they have a significantly higher proportion of lipid-rich, noncalcified plaque even when matched for traditional risk factors.98 Relying solely on CACS may underestimate plaque burden because it does not detect noncalcified plaque, which requires contrast-enhanced imaging to visualize, especially in younger individuals (eg, 25-45 years of age, when plaque may not yet have calcified). Among 534 patients from Pakistan with diabetes and dyslipidemia (mean age 53 years), 29% of those with CAC scores of zero demonstrated noncalcified coronary plaque, and 5.8% had obstructive CAD (>50% stenosis), highlighting the limited sensitivity of CAC for detecting early and clinically significant atherosclerosis in high-risk SA populations.99 In the SCAPIS (Swedish Cardiopulmonary Bioimage Study) screening study of more than 25,000 Swedes (median age 57 years), 5.5% of individuals had plaque on coronary CTA despite CAC = 0. Similarly, in the United States, a population-based cohort study of asymptomatic individuals in the Miami area (mean age 53 years, 50% women, 47% Hispanic/Latino, 43% non-Hispanic White), 58% of the whole cohort had CAC = 0, and 49% of the total cohort had any plaque by coronary CTA. Among participants with CAC = 0, 16% had detectable plaque on coronary CTA, 0.8% had ≥50% coronary stenosis, and 2.3% had high-risk plaque (HRP). Additionally, in the DILWALE study, conducted in the Dallas area (341 SAs, mean age 56 years), 63% had any plaque on coronary CTA; 10% of individuals with CAC = 0 had plaque detected by coronary CTA.100, 101, 102 In SAs with nontraditional risk factors (eg, elevated Lp[a], strong family history, familial dyslipidemia syndromes), in whom further evaluation would be helpful and solely noncalcified plaque is likely to be present, coronary CTA thus may help identify coronary atherosclerosis that might otherwise be missed.22,103 Because underdiagnosis delays the initiation of preventive therapies and because of the aggressive nature of CAD progression in SAs, delays in correct risk classification can result in missed opportunities for early intervention. The 2026 American College of Cardiology/American Heart Association/multisociety dyslipidemia management guideline emphasizes the role of CAC as a decision aid in low- and intermediate-risk patients to guide statin initiation or deferral, as well as ties in the severity of CAC scores with LDL cholesterol goals (eg, for patients with CAC scores >1,000 Agatston units, the LDL cholesterol goal is <55 mg/dL; Class 1, Level of Evidence: B-NR).104 Furthermore, the guideline also recommends consideration of coronary CTA for individuals who are likely to have noncalcified plaque, in whom CACS may underestimate risk, such as those with diabetes or inflammatory disorders or HIV infection (Class 2b, Level of Evidence: B-NR).104 Coronary CTA as a comprehensive risk assessment tool Coronary CTA provides a comprehensive anatomical evaluation of the coronary vasculature and enables the detection of subclinical atherosclerosis in asymptomatic individuals, which is particularly useful in high-prevalence populations with aggressive disease progression. Coronary CTA has distinct advantages over traditional risk assessment tools and applications across different domains of CV risk management (Table 2). This is particularly crucial in young SAs, in whom noncalcified plaque predominates and early rupture-prone lesions are common.105,106 In a cohort of patients presenting with acute coronary syndrome (n = 1,315, including 100 SAs), optical coherence tomographic analysis demonstrated a higher frequency of plaque erosion, greater lipid index (product of mean lipid arc and lipid length), and increased prevalence of layered plaque (a sign of previous plaque disruption) among SAs, with culprit lesions exhibiting more features of plaque instability compared with East Asian and White patients.80 Several coronary CTA–derived features thus enhance its diagnostic and prognostic value, underscoring its utility as a comprehensive vascular assessment modality (Table 3). In a cross-sectional study (543 SAs and 420 Whites) based in the United Kingdom, SAs showed significantly higher noncalcified volume than Whites (90.4% vs 81.0%; P < 0.001), despite similar stenosis severity. This finding was observed despite SAs having a lower mean Agatston calcium score (57 vs 121) than Caucasians in the cohort.25 A recent single-center U.S.-based study (n = 330) has also found higher total percentage atheroma volume (PAV) (11.9% vs 6.3%), noncalcified PAV (5.1% vs 3.8%), and calcified PAV (4.9% vs 2.4%) in SAs compared with age-matched non-Hispanic Whites.107 Similarly, an Australian-based study showed that SA undergoing clinically indicated coronary CTA had higher aggregate plaque volume (45% vs 40% vs 38%; P < 0.001) than age-, gender-, and BMI-matched Caucasians and Southeast or East Asians (n = 50 per group). The percentage of epicardial fat volume was higher in SAs than in Caucasians (14% vs 10%).108 Collectively, these findings support the notion that coronary CTA may be more informative in SAs, as they tend to have more noncalcified plaque. Table 4 summarizes key studies on CV risk in SAs. Table 2Key Findings by Coronary CTA for Atherosclerotic Coronary Plaque Imaging in SAsApplication DomainKey Findings (SAs vs Reference)Notable StudiesPrimary preventionHigh prevalence of subclinical CAD in SAs. Coronary CTA often finds plaque in “intermediate-risk” SA individuals that would be missed by risk scores or CAC alone.Villadsen et al (2017)25: 90% of SA plaque volume was noncalcified compared with 81% in NHWs.Risk stratificationTraditional risk calculators (Framingham risk score/ASCVD) underestimate risk in SAs relative to actual plaque burden. Coronary CTA–derived total plaque and plaque composition provide incremental prognostic value beyond clinical scores.Gobardhan et al (2017)24: Despite similar risk scores, SAs had higher CAC and more obstructive CAD on coronary CTA vs NHWs.Al Rifai et al (2018)160: Marked discordance between estimated 10-y risk and CAC burden in SAs.ACS presentation and plaque morphologySAs present with ACS at younger ages and often with diffuse, multivessel disease. Plaque characteristics are enriched for high-risk features, including lipid-rich cores, positive remodeling, and plaque erosion.Nakajima et al (2021)80: ACS in SAs predominantly due to plaque erosion, with greater prevalence of high-risk plaque features compared with East Asians and NHWs.AI-based plaque analysis (LAP, FAI, etc)Advanced coronary computed tomographic angiographic metrics enhance risk prediction beyond stenosis severity. LAP burden and PVAT FAI identify biologically active, rupture-prone disease, particularly relevant in SAs given predominance of noncalcified plaque. Validation in SA-specific cohorts remains limited.SCOT-HEART (Williams et al [2020]117): LAP burden is the strongest predictor of MI (HR: ∼1.6 per doubling; >4% LAP ≈ 5-fold MI risk).CRISP-CT (Oikonomou et al [2018]134): PVAT FAI > −70.1 HU associated with ∼9-fold higher cardiac mortality.Plaque progression and regression monitoringSAs demonstrate rapid atherosclerosis progression when untreated. Aggressive lipid-lowering therapy slows plaque growth, increases plaque calcification, and reduces high-risk features. Serial coronary computed tomographic angiographic data in SAs are limited but supportive.MASALA (2019)87: SA men exhibited faster CAC progression than most ethnic groups.Lee et al (2018)161: Statins reduce plaque volume progression by ∼20% and high-risk plaque by ∼35%.Cho et al (2022)159: AI-assisted serial coronary CTA over 13 y showed plaque stabilization with therapy.Coronary CTA can detect differences in subclinical atherosclerosis, plaque morphology, AI-derived biomarkers, and plaque progression, enabling focused risk assessment.ACS = acute coronary syndrome; AI = artificial intelligence; CAC = coronary artery calcium; CAD = coronary artery disease; CRISP-CT = Cardiovascular Risk Prediction Using Computed Tomography; MASALA = Mediators of Atherosclerosis in South Asians Living in America; MI = myocardial infarction; NHW = non-Hispanic White; SCOT-HEART = Scottish Computed Tomography of the Heart; other abbreviations as in Table 1. Key Findings by Coronary CTA for Atherosclerotic Coronary Plaque Imaging in SAs Coronary CTA can detect differences in subclinical atherosclerosis, plaque morphology, AI-derived biomarkers, and plaque progression, enabling focused risk assessment. ACS = acute coronary syndrome; AI = artificial intelligence; CAC = coronary artery calcium; CAD = coronary artery disease; CRISP-CT = Cardiovascular Risk Prediction Using Computed Tomography; MASALA = Mediators of Atherosclerosis in South Asians Living in America; MI = myocardial infarction; NHW = non-Hispanic White; SCOT-HEART = Scottish Computed Tomography of the Heart; other abbreviations as in Table 1. Table 3Key Imaging Biomarkers on Coronary CTA and Their Clinical SignificanceImaging BiomarkerDefinitionClinical SignificanceRelevance for SAsTPVVolumetric quantification of total coronary plaque burdenPredicts MACE more accurately than stenosis severityOften elevated despite low or zero CACLAPPlaque component with CT attenuation <30 HUIdentifies lipid-rich, rupture-prone plaqueMay be present even when CAC = 0, underscoring the limitation of CAC alonePRRemodeling index > 1.1Marker of biologically active, high-risk plaqueHigh prevalence of aggressive NCP in SAsNRSLow-density core with high-density rimStrong predictor of acute coronary syndromeReflects unstable plaque biology contributing to premature CADPVAT FAICT assessment of perivascular fat attenuationSurrogate marker of coronary inflammation and endothelial injuryAligns with a heightened adverse cardiometabolic risk profilePAVPlaque volume normalized to vessel volumeEnables serial tracking of plaque progression or regressionUseful for monitoring treatment responseFFR-CTComputational modeling of coronary physiologyDetermines the functional significance of stenosesHelps clarify ischemic relevance of intermediate or borderline lesionsCAC scoreQuantification of calcified plaqueStrong predictor of long-term cardiovascular eventsLimited sensitivity because of prevalent NCP in young SAsQuantitative markers such as TPV, LAP, PR, and PVAT FAI offer powerful prognostic information and are particularly relevant in SAs, who often harbor high-risk, NCP despite low risk scores.MACE = major adverse cardiovascular events; TPV = total plaque volume; other abbreviations as in Tables 1 and 2. Key Imaging Biomarkers on Coronary CTA and Their Clinical Significance Quantitative markers such as TPV, LAP, PR, and PVAT FAI offer powerful prognostic information and are particularly relevant in SAs, who often harbor high-risk, NCP despite low risk scores. MACE = major adverse cardiovascular events; TPV = total plaque volume; other abbreviations as in Tables 1 and 2. Table 4A Few Key Epidemiologic, Imaging, Genetic, and Prevention Studies Informing CV Risk in SAsFirst Author/StudyYearDesignPopulation and SA InclusionKey FocusMain FindingsPatel et al (UK Biobank)32021Prospective cohort8,124 SAs vs 449,349 with European ancestry; no prior ASCVDRisk predictionDespite ∼2-fold higher observed 10-y ASCVD event rates in SAs (adjusted HR: 2.03), standard risk equations (PCE, QRISK3) did not predict higher risk, demonstrating systematic underestimation.Haque et al (MASALA)902021Cross-sectional (cohort analysis)1,114 SAs in the United States; no clinical ASCVD at baselineCAC for risk stratificationAmong borderline-risk SAs (5%-7.5%), 54% had CAC = 0, while 13% had CAC > 100; among intermediate-risk SAs (7.5%-20%), 37% had CAC > 100, supporting CAC-guided statin personalization.Kanaya et al (MASALA/MESA)1622019Prospective cohort698 SAs (MASALA) with serial CACS over ∼5 y; comparison with 4 ethnic groups (MESA)CAC progressionIncident CAC developed in 41% of SA men and 16% of SA women with baseline CAC = 0. SA men had faster CAC progression than Black, Latino, or Chinese men, comparable with Whites.Paré et al (INTERHEART)482019Case-control (multiethnic)6,086 first-MI cases and 6,857 control subjects across 7 ethnic groups (including 1,829 SAs)Lp(a)SAs had higher median Lp(a) levels than most ethnic groups. Lp(a) > 50 mg/dL was associated with ∼1.5-fold higher MI odds overall, rising to an OR of 2.14 in SAs, independent of other risk factors.Saleheen et al (PROMIS)1632017Mendelian randomization analysis∼10,000 Pakistani SA cases/control subjectsGenetics (Lp[a])Identified high prevalence of small apo(a) isoforms in SAs, genetically linking elevated Lp(a) levels to increased CAD risk.Wang et al (PRS)1642020Genetic risk score development7,244 SAs (UK Biobank), 491 Bangladeshis, and 1,800 Indian CAD cases/1,163 control subjectsGenetics (polygenic risk)Developed an SA-specific CAD PRS. Each SD increase conferred a higher CAD risk (OR: ∼1.6 per SD); the top 5% had ∼3- to 4-fold higher odds than average PRS values.HOPE-3 trial (Yusuf et al)1432016RCT (2 × 2 factorial)12,705 intermediate-risk adults globally (15% SAs; men ≥55 y of age, women ≥65 y of age, ≥1 risk factor)Primary prevention (rosuvastatin and candesartan/hydrochlorothiazide)Rosuvastatin reduced major CV events by 25% over 5.6 y. Combined statin + BP therapy provided greater benefit in hypertensive participants (HR: ∼0.71).TIPS-3 trial (Joseph et al)1652021RCT (2 × 2 × 2 factorial)5,713 intermediate-risk adults in India, the Philippines, and other locations (mean age ∼ 64 y; ∼50% women)Primary prevention (polypill)Polypill therapy reduced major CV events by ∼21% over 4.6 y, supporting scalable prevention strategies in SA-dominant regions.CARRS trial (Ali et al)1662024RCT (clinic-level QI intervention)1,146 SA patients with type 2 diabetes and poor control in India/PakistanMultifactor preventionSustained improvements in HbA1c, BP, and LDL at 6.5 y; significant reduction in microvascular complications, though macrovascular event rates were similar.Garg et al (MASALA/MESA)1672016Cross-sectional (cohort study)798 SAs (MASALA) vs 6,814 others (MESA), all free of CVDMetabolic syndrome and ectopic fatSAs had higher visceral and hepatic fat for a given BMI, which correlated with higher CAC and subclinical atherosclerosis.Kanaya et al (MASALA/MESA)872014Cross-sectional (comparative)803 SAs (MASALA) vs 6,814 others (MESA) in the United States; 40-84 y of age, no CVDCAC prevalenceSA men had CAC prevalence comparable with White men and higher than Black, Latino, or Chinese men; older SA women (>70 y) showed higher CAC than their peers.Tillin et al (SABRE)1682013Prospective cohort (20 y)∼4,196 UK men (1,517 SAs, 2,049 Europeans, 630 African Caribbeans; mean baseline age 52 y)Long-term outcomesSAs had ∼70% higher CHD incidence (HR: ∼1.7) than Europeans. Adjustment for metabolic risk factors only partially attenuated excess risk, leaving ∼45% residual risk.Overview of important studies characterizing the burden, mechanisms, and modifiable determinants of ASCVD in SAs, including evidence on subclinical atherosclerosis, risk misclassification, genetic susceptibility, and the impact of preventive therapies.BMI = body mass index; BP = blood pressure; CARRS = Centre for Cardiometabolic Risk Reduction in South-Asia Study; CHD = coronary heart disease; CV = cardiovascular; CVD = cardiovascular disease; HbA1c = glycated hemoglobin; HOPE-3 = Heart Outcomes Prevention Evaluation-3; LDL = low-density lipoprotein; MESA = Multi-Ethnic Study of Atherosclerosis; PCE = pooled cohort equations; PROMIS = Pakistan Risk of Myocardial Infarction Study; PRS = polygenic risk score; RCT = randomized controlled trial; QI = quality improvement; SABRE = Southall and Brent Revisited; TIPS-3 = The International Polycap Study-3; other abbreviations as in Tables 1, 2, and 3. A Few Key Epidemiologic, Imaging, Genetic, and Prevention Studies Informing CV Risk in SAs Overview of important studies characterizing the burden, mechanisms, and modifiable determinants of ASCVD in SAs, including evidence on subclinical atherosclerosis, risk misclassification, genetic susceptibility, and the impact of preventive therapies. BMI = body mass index; BP = blood pressure; CARRS = Centre for Cardiometabolic Risk Reduction in South-Asia Study; CHD = coronary heart disease; CV = cardiovascular; CVD = cardiovascular disease; HbA1c = glycated hemoglobin; HOPE-3 = Heart Outcomes Prevention Evaluation-3; LDL = low-density lipoprotein; MESA = Multi-Ethnic Study of Atherosclerosis; PCE = pooled cohort equations; PROMIS = Pakistan Risk of Myocardial Infarction Study; PRS = polygenic risk score; RCT = randomized controlled trial; QI = quality improvement; SABRE = Southall and Brent Revisited; TIPS-3 = The International Polycap Study-3; other abbreviations as in Tables 1, 2, and 3. Additionally, coronary CTA allows the identification of HRP features, such as low-attenuation plaque, positive remodeling, the napkin-ring sign, and fibrous cap thinning, which are strongly associated with increased risk for MACE and early plaque vulnerability and rupture.109,110 In a cross-sectional study of Asian Indians (n = 96) presenting with chest pain, 63% were ≤40 years of age and had a higher prevalence of qualitatively assessed HRP features, including positive remodeling (70% vs 15%), low-attenuation plaque (64% vs 11%), and spotty calcification (36% vs 4%), compared with those with stable angina; the presence of a composite vulnerability score (composed of the 3 aforementioned HRP features) and Lp(a) >30 mg/dL was independently predictive of acute coronary syndromes in multivariable models.111 Similarly, the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial showed that HRP was associated with a 2.7-fold higher risk for MACE (HR: 2.73) and significantly improved risk reclassification when incorporated into the ASCVD risk score (net reclassification index = 0.34).112 In the SCOT-HEART (Scottish Computed Tomography of the Heart) study, HRP within nonobstructive lesions was associated with a 3-fold increase in MACE (HR: 3.01; P = 0.001), whereas the combination of HRP and obstructive CAD conferred an 11-fold greater risk (HR: 11.50; P < 0.001).113 The integration of AI-based coronary computed tomographic angiographic analysis has further transformed risk stratification by enabling precise quantification of coronary atherosclerosis, including total plaque volume (TPV), plaque composition, and vascular remodeling.114, 115, 116 These advanced metrics consistently outperform percent stenosis in predicting MACE, with higher TPV, PAV, and the presence of HRP features demonstrating strong associations with MACE.98,117, 118, 119, 120, 121 Incorporating TPV and HRP characteristics into clinical assessments enhances risk discrimination beyond traditional risk scores, particularly in asymptomatic individuals. Figure 2 shows an example of volumetric plaque analysis in an SA patient. Notably, higher TPV and noncalcified plaque volume are associated with an increased risk for myocardial infarction, underscoring the potential prognostic power of volumetric plaque analysis.120,122 An Example of Coronary Computed Tomographic Angiography–Based Plaque Characterization in a South Asian Patient Curved multiplanar reformatted coronary computed tomographic angiographic images in a 38-year-old male South Asian patient with no history of smoking, hypertension, or diabetes and an unremarkable lipid profile but a family history of premature coronary artery disease in his father, revealing significant multivessel plaque with both calcified and noncalcified morphologies. (A) Curved multiplanar reformat of the right coronary artery. (B) Left anterior descending coronary artery. (C) Left circumflex artery. (D) Quantitative plaque analysis from artificial intelligence–derived analysis (Cleerly) reveals a total plaque volume of 530.9 mm3, composed of 260.9 mm3 noncalcified plaque (which includes 2.4 mm3 low-density noncalcified plaque) and 270 mm3 calcified plaque. The left main/left anterior descending segment had the greatest plaque burden (255.3 mm3), followed by the right coronary artery (162.5 mm3) and left circumflex coronary artery (113.1 mm3). The circumflex coronary artery demonstrated the highest percentage atheroma volume (25.5%) with a disproportionately large noncalcified component (66.8 mm3). AI-enabled analysis of coronary CTA in symptomatic patients extends beyond anatomical assessment by quantifying the cumulative hemodynamic significance of coronary lesions through FFR-CT, a computational fluid dynamics–based technique. Across multiple studies, FFR-CT has demonstrated strong diagnostic performance: in the NXT (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps) trial, it showed high accuracy against invasive FFR; in DISCOVER-FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained via Noninvasive Fractional Flow Reserve), it achieved a superior area under the curve (0.90 vs 0.75 for coronary CTA); and in the PLATFORM (Prospective Longitudinal Trial of FFRct: Outcome and Resource Impacts) study, its use reduced unnecessary invasive coronary angiography in patients with stable chest pain.123, 124, 125 Real-world data from the multicenter ADVANCE (Assessing Diagnostic Value of Non-Invasive FFRCT in Coronary Care) registry further showed that FFR-CT altered management in two-thirds of patients, reduced the need for invasive angiography in patients without obstructive disease, informed revascularization decisions, and identified individuals at low short-term MACE risk.126 Newer coronary CTA–based approaches to ischemia assessment, including AI-enabled quantitative computed tomographic algorithms, provide valuable adjunctive tools for ischemia evaluation in SA populations, which tend to have smaller proximal left anterior descending coronary artery diameters, greater degrees of stenosis, and a higher prevalence of multivessel CAD compared with Caucasians.127,128 Nonetheless, even in the absence of obstructive CAD, visualization of atherosclerosis can change clinical management, prompting the initiation or intensification of lipid-lowering therapies and enhancing adherence to preventive regimens.129 The SCOT-HEART trial demonstrated that coronary CTA–guided evaluation of patients with suspected cardiac symptoms was associated with a lower incidence of coronary heart disease death or nonfatal myocardial infarction at 5 years, largely through improved identification of atherosclerosis and downstream initiation of preventive therapies, even in the absence of obstructive disease.129 Thus, coronary CTA may be a superior tool for refining CV risk stratification in SAs. One must carefully balance the additional information likely to be derived from coronary CTA versus CACS or risk calculator alone in primary prevention in SAs, considering the pros of identifying noncalcified plaque in younger individuals at risk vs the cons of subjecting them to radiation, expense, and intravenous contrast and the incremental discrimination yielded by the study. Although not appropriate for mass screening or all comers in the primary prevention clinic, as shown earlier, selective application of coronary CTA in those at highest risk for having noncalcified plaque or early atherosclerosis that may be missed by CACS is the best suited case scenario for coronary CTA, particularly when the study can be done at contemporary low radiation doses (often <2 mSv and even <1 mSv at expert centers, approaching the radiation dose of a CAC scan). The 2021 Society of Cardiovascular Computed Tomography expert consensus document states that coronary CTA may be appropriate in selected asymptomatic individuals at high CV risk, particularly when noncalcified plaque burden is suspected.130 In clinical practice, this may include younger adults with multiple risk enhancers such as SA ancestry, diabetes, strong family history of premature ASCVD, chronic inflammatory conditions, HIV infection, or significant smoking exposure.131 However, at this time, there are no clinically validated nomograms available for TPV, noncalcified plaque volume, and other plaque features such as perivascular adipose tissue (PVAT) fat attenuation index (FAI) scores or low-attenuation plaque for SAs, and the premise that changes in these can be translated to changes in clinical outcomes needs to be validated in SAs both for natural history progression and for regression with drug/other interventions. Perivascular fat inflammation SAs have been shown to have a higher epicardial fat volume compared with Caucasians.108 PVAT FAI is a coronary computed tomographic angiographic imaging biomarker that quantifies coronary inflammation by measuring changes in attenuation. PVAT FAI has transformed coronary CTA from a purely diagnostic tool into a dynamic biomarker of disease activity and therapeutic response. Immune cells within PVAT, particularly macrophages and T cells, drive the secretion of inflammatory mediators, including tumor necrosis factor-α, IL-6, and monocyte chemoattractant protein-1, all of which contribute to endothelial dysfunction and atherogenesis.132,133 In the CRISP-CT (Cardiovascular Risk Prediction Using Computed Tomography) study (n = 3,912), FAI values ≥−70.1 HU independently predicted cardiac mortality (HR: ∼9; P < 0.001).134 Even if a plaque is not severely obstructive, a high PVAT FAI could indicate active inflammation, meaning that the plaque is more prone to rupture. It guides preventive strategies, enabling more aggressive tactics to be implemented. Dysfunctional PVAT is linked to a range of CVDs, including hypertension, CAD, and peripheral artery disease.135 A deficiency in protective adipokines, such as adiponectin, further disrupts vascular function by impairing vasodilation and increasing vascular resistance, compounding the pathogenic effects of PVAT dysfunction.133 This requires further studies in SAs, but one could hypothesize that SAs might have higher PVAT FAI readings for a given plaque burden. These findings establish coronary CTA as a comprehensive tool for ASCVD risk stratification through anatomical plaque imaging and the assessment of vascular biology and systemic inflammation. Its role in primary prevention complements that of CAC, AI-enabled quantitative computed tomography, and HRP features. In the ORFAN (Oxford Risk Factors and Non-Invasive Imaging) study, which included >40,000 individuals, FAI predicted MACE independent of obstructive CAD and clinical risk factors.136 In asymptomatic patients, FAI detects subclinical vascular inflammation and acts as a risk enhancer; thus, it may be especially relevant in younger patients, those with inflammatory conditions, diabetes, smoking, HIV infection, and discordant risk scores or CAC = 0 with suspected risk, such as SAs. In essence, FAI is a marker of inflammatory activity in pericoronary adipose tissue driving atherosclerosis, and can thus guide the intensity of preventive therapy. Clinical Implementation Coronary CTA serves as a modality for identifying residual risk and monitoring therapeutic efficacy in a population with a disproportionate burden of noncalcified coronary plaque. The ability of coronary CTA to provide vessel-level and plaque-level characterization is particularly valuable in SAs, who often exhibit multivessel, mixed-morphology disease. As illustrated in Figure 2, AI-enhanced coronary CTA can quantify total and vessel-specific plaque burden—including calcified, noncalcified, and low-density components—offering a comprehensive anatomical and biological assessment that surpasses traditional risk markers.122 Integrating coronary CTA into the care of SAs marks a pivotal advance in precision risk assessment by enabling direct visualization and quantification of coronary plaque burden, rather than relying solely on indirect surrogate biomarkers such as LDL cholesterol, glycated hemoglobin, and blood pressure.2 The detection of elevated plaque burden or HRP features on coronary CTA can justify the earlier initiation of intensive medical therapy, including antiplatelet agents and high-intensity statins (Table 5).137,138 This precision-guided approach is particularly relevant in SAs, whose atherosclerotic phenotype is often discordant with traditional risk metrics, and it enables objective, longitudinal tracking of disease progression to support dynamic treatment adjustment. Beyond initiating or escalating statin therapy, findings on coronary CTA may inform the use of adjunctive lipid-lowering therapies such as ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibitors, as well as emerging anti-inflammatory strategies targeting interleukin-1β or the NLRP3 inflammasome.139, 140, 141, 142 Preventive therapy is particularly effective in SAs, with evidence showing that even individuals without established CVD derive significant MACE reduction from lipid-lowering and anti-inflammatory agents.143 In higher risk individuals who have more plaque burden than that would be expected for age- and sex-matched cohorts, aggressive dietary and lifestyle changes and lipid-lowering therapy can be implemented. The Lipid Association of India recommends target LDL cholesterol values of <70 mg/dL or lower in high-risk primary prevention SA individuals,144 including those with diabetes or multiple risk factors such as family history, elevated Lp(a), and others.85,145,146 In our practice, this is often also extrapolated to those with extensive plaque burden on coronary CTA or CACS for their age and sex category or with adverse plaque features, as indicated by high FAI scores. As extensive data sets or nomograms for these metrics do not yet exist for SAs, clinical judgment is required to tailor the intensity of lipid-lowering and other therapies (such as icosapent ethyl, colchicine, sodium-glucose cotransporter 2 inhibitors, or glucagon-like peptide-1 receptor agonists) in individuals with obesity, diabetes, or metabolic syndrome.137 On the contrary, the absence of plaque on coronary CTA can de-risk most individuals, and given its warranty period with very low incident MACE, one can defer pharmacotherapy after shared decision-making and consider rescanning in 5 to 7 years, provided that no high-risk conditions coexist, such as primary hyperlipidemias (eg, familial hypercholesterolemia), diabetes, smoking, or strong family history.130,147 Table 5A Proposed Algorithm for Pharmacotherapy Based on Total Plaque Burden and/or CAD Staging CategoriesASCVD Risk GroupPlaque Burden by CAC Scoring (Agatston Units)Plaque Burden by CAD-RADS Qualitative Category (P1-P4) or AI-QCT TPVTherapeutic ConsiderationsLow-risk group0No plaqueReinforce therapeutic lifestyle modification and consider repeat imaging in 5-7 y if new risk factors emerge.Low- to moderate-risk group1-99Mild noncalcified plaque or low plaque burden: P1 or TPV < 250 mm3Moderate-intensity statin, LDL-C goal <100 mg/dL (optionally <70 mg/dL).Moderate- to high-risk group100-299Moderate plaque burden: P2, TPV = 250-500 mm3High-intensity statin, add ezetimibe and/or bempedoic acid as needed, LDL-C goal <70 mg/dL (optionally <55 mg/dL) consider aspirin.High-risk group300-999Moderate to severe plaque burden: P3 or TPV 501-750 mm3High-intensity statin and aspirin, add ezetimibe and/or PCSK9 inhibitor, LDL-C goal <55 mg/dL (optionally <30-40 mg/dL). Consider colchicine for addressing inflammatory risk.Extreme-risk group>1,000Severe plaque burden: P4 or TPV >750 mm3 and/or presence of high-risk plaque features/high FAI scoreHigh-intensity statin to: High-intensity statin and aspirin, add ezetimibe and/or PCSK9 inhibitor, LDL-C goal <30-40 mg/dL (optionally <15 mg/dL). Consider colchicine for addressing inflammatory risk.Treatment intensity becomes progressively more aggressive as total plaque burden increases (plaque burden may be assessed using coronary artery calcium scoring or TPV on coronary computed tomographic angiography).AI-QCT = artificial intelligence–assisted quantitative computed tomography; CAD-RADS = Coronary Artery Disease Reporting and Data System; LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9; other abbreviations as in Tables 1, 2, and 3. A Proposed Algorithm for Pharmacotherapy Based on Total Plaque Burden and/or CAD Staging Categories Treatment intensity becomes progressively more aggressive as total plaque burden increases (plaque burden may be assessed using coronary artery calcium scoring or TPV on coronary computed tomographic angiography). AI-QCT = artificial intelligence–assisted quantitative computed tomography; CAD-RADS = Coronary Artery Disease Reporting and Data System; LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9; other abbreviations as in Tables 1, 2, and 3. Beyond its diagnostic advantages, coronary CTA provides a powerful behavioral intervention: visualizing plaque burden, stability, or regression reinforces risk perception and enhances adherence to guideline-directed medical therapy, especially among asymptomatic patients.90 Ultimately, the goal of these preventive strategies is to enable a proactive, biology-driven approach centered on plaque stabilization and regression, thereby reducing downstream MACE.148, 149, 150 Study limitations Additionally, for coronary CTA plaque metrics to mature and be included in guideline-directed pathways of care, the field will need to demonstrate intervendor and inter-reader reproducibility and accuracy, ability to track changes with therapeutic alterations, and correlation with a reduction in downstream MACE, cost-effectiveness, and ease of use in large health care systems. Several trials are under way testing many of these aspects (eg, SCOT-HEART2, TRANSFORM, ARTCAP, RESPECT, DANE-HEART), but, none is specific to SAs.151, 152, 153 Despite its substantial value in refining ASCVD risk assessment, the adoption of coronary CTA among SAs remains constrained by socioeconomic, cultural, and system-level barriers.154,155 Access to coronary CTA is often limited to tertiary or private centers, at which high out-of-pocket costs and inconsistent insurance coverage (issues that persist even within diaspora communities) significantly impede its use. Low health literacy, language barriers, medical mistrust, and reliance on traditional remedies further delay engagement with preventive imaging, while clinicians may underestimate true risk because commonly used calculators underrepresent SAs’ susceptibility.156 Resource limitations are particularly relevant in South Asia, where many individuals cannot afford newer lipid-lowering therapies such as proprotein convertase subtilisin/kexin type 9 inhibitors and drugs for cardio-kidney-metabolic syndrome, such as sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonist–based therapies. Addressing these barriers requires culturally tailored education, expanded access, standardized pathways, and integration of SA-specific considerations into preventive cardiology. Future Directions Looking ahead, future research must address several important gaps in our understanding of coronary heart disease risk among SAs. Although substantial evidence demonstrates a higher burden and earlier onset of coronary heart disease and its risk factors in this population, most existing studies have been male dominated. Dedicated investigations in SA women are needed to determine whether the excess coronary heart disease risk associated with SA ethnicity is equally prominent in women or follows a different trajectory. Although current prevention guidelines recognize the elevated coronary heart disease risk in SAs and endorse the use of an ethnicity-specific correction factor in the pooled cohort equations or in the PREVENT tool, the optimal magnitude of this adjustment remains uncertain and warrants further refinement. The performance of the newer PREVENT equations in SAs is still under investigation. Emerging imaging and biomarker-based metrics—such as FAI, AI-enabled quantitative computed tomography for noncalcified plaque volume and TPV, HRP, and inflammatory biomarkers including hsCRP—offer insights into the biology of metabolically active atherosclerotic disease that conventional risk scores cannot capture.157 Apart from PVAT FAI, other tools, such as positron emission tomography with 18F-fluorodeoxyglucose and other tracers and magnetic resonance imaging, are being explored as options for assessing PVAT. Overall, future strategies for ASCVD prevention and monitoring should integrate a plaque-centric therapeutic framework with vascular inflammation assessment, recognizing atherosclerosis as a dynamic interplay between plaque burden, composition, and the surrounding inflammatory milieu. The recently published American Heart Association scientific statement advocates a staged classification of nonobstructive CAD that integrates coronary calcium burden, coronary CTA–derived plaque metrics (including TPV, PAV, and stenosis severity) and PVAT FAI.138 In SAs, comprehensive preventive strategies should ultimately integrate coronary CTA–derived plaque metrics with multiomic and exposomic data to enhance individualized risk prediction. Nonetheless, careful delineation of patient subgroups most likely to benefit from coronary CTA beyond CACS alone in primary prevention is required before widespread adoption. Emerging AI-enabled plaque quantification approaches, incorporating age- and sex-adjusted plaque percentiles and perivascular inflammation assessment, may enable the judicious use of serial coronary CTA in lipid and cardiometabolic clinics, facilitating targeted, mechanism-informed treatment decisions.158 As radiation exposure continues to decline and image acquisition becomes faster, coronary CTA may be used to directly monitor plaque progression, regression, and therapeutic response, especially in the context of LDL cholesterol, inflammation, and Lp(a)-lowering therapies. The convergence of advanced imaging, AI analytics, data from wearables, and precision genomics offers a promising path toward biology-driven, individualized ASCVD prevention in this high-risk population.159 Conclusions SAs represent a uniquely high-risk population for premature ASCVD, driven by genetically mediated lipid abnormalities, elevated Lp(a), insulin resistance at lower body mass indexes, visceral and ectopic adiposity, and a proinflammatory cardiometabolic phenotype. Together, these factors contribute to the early development of aggressive, predominantly noncalcified atherosclerosis, pathobiology that may be incompletely captured by traditional risk scores and CAC assessment alone. By enabling direct visualization of total plaque burden, HRP characteristics, and early noncalcified disease—features that appear particularly prevalent in SAs—coronary CTA offers a more comprehensive assessment of coronary atherosclerosis and may allow more refined risk stratification beyond clinical algorithms alone (Central Illustration). When integrated with genomic, lipidomic, and metabolomic profiling—and augmented by AI-enabled plaque quantification, perivascular inflammation assessment (FAI), and FFR-CT—coronary CTA enables individualized identification of high-risk vascular biology and actionable therapeutic targets. Serial coronary CTA further provides a dynamic framework to track plaque progression or regression, facilitating the timely intensification of lipid-lowering, Lp(a)-targeted, glucose-lowering, and anti-inflammatory therapies. At the same time, the use of coronary CTA in primary prevention among SAs requires careful patient selection, balancing the incremental biological and prognostic information gained beyond CACS or traditional risk calculators against considerations of radiation exposure, cost, and contrast use. Although coronary CTA is not appropriate for population-wide screening, its selective application in individuals at highest risk for noncalcified plaque or early atherosclerosis, features frequently missed by CACS, offers substantial added value. Importantly, contemporary coronary computed tomographic angiographic protocols now achieve ultralow radiation doses, often <2 mSv and, at expert centers, approaching <1 mSv, comparable with CAC scanning. Together, the integration of ethnicity-specific risk enhancers with advanced imaging supports a paradigm shift in SA CV prevention toward a personalized, biology-driven, and proactive strategy with the potential to reduce ASCVD burden in this high-risk population substantially. Role of Coronary CTA in Assessment of ASCVD Risk in South Asians Coronary computed tomography angiography (CTA) reveals plaque composition, high-risk plaque features, and vascular inflammation, providing deep phenotyping beyond traditional risk factors. Evidence from PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain), SCOT-HEART (Scottish Computed Tomography of the Heart), and ADVANCE (Assessing Diagnostic Value of Non-Invasive FFRCT in Coronary Care) shows that coronary CTA and computed tomography–derived fractional flow reserve (FFR-CT) enhance risk prediction and guide clinical decision-making. These insights enable accurate risk reclassification and targeted preventive therapy, including plaque-directed treatment and serial imaging to monitor disease progression. ASCVD = atherosclerotic cardiovascular disease; BMI = body mass index; CACS = coronary artery calcium scoring; CP = calcified plaque; FAI = fat attenuation index; LDL-C = low-density lipoprotein cholesterol; NCP = noncalcified plaque; PAV = percentage atheroma volume; PVAT = perivascular adipose tissue; TPV = total plaque volume. Funding Support and Author Disclosures Dr Mehta has received institutional research funding from Novartis and Amgen. Dr Hosadurg is supported by National Institutes of Health grant 5P01HL152958. Dr Pagidipati has received research support from Alnylam, Amgen, Bayer, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Merck, and Metsera; and has held consulting and advisory roles for Alnylam, Amgen, Bayer, Boehringer Ingelheim, Corcept, Corsera, Eli Lilly, Esperion, AstraZeneca, Merck, Metsera, New Amsterdam, Novartis, Novo Nordisk, and Bristol Myers Squibb. Dr Slipczuk has received honoraria from Elsevier (editor-in-chief, Progress in Cardiovascular Diseases); has held clinical trial site principal investigator roles with Amgen and Philips; has received prior research funding from Amgen and Philips; and holds equity in APQ Health. Dr Dey has received royalties from Cedars-Sinai Medical Center; holds equity in APQ Health, and has received grant support from the National Heart, Lung, and Blood Institute (R01HL175875 and R01HL151266). Dr Joshi has received grant funding from Novartis and Eli Lilly. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References